Affordable Access

Publisher Website

Neurotropin® relieves oxaliplatin-induced neuropathy via Giprotein-coupled receptors in the monoaminergic descending pain inhibitory system

Authors
Journal
Life Sciences
0024-3205
Publisher
Elsevier
Volume
98
Issue
1
Identifiers
DOI: 10.1016/j.lfs.2013.12.229
Keywords
  • Neurotropin
  • Oxaliplatin
  • Allodynia
  • Monoamine
  • Giprotein-Coupled Receptors
Disciplines
  • Biology

Abstract

Abstract Aims Oxaliplatin is a key drug in the treatment of colorectal cancer, but it causes acute and chronic peripheral neuropathies. We previously reported that repeated administration of neurotropin prevents oxaliplatin-induced mechanical allodynia by inhibiting axonal degeneration in rats. In the present study, we investigated the analgesic effect of a single administration of neurotropin on oxaliplatin-induced neuropathy in rats. Main methods Oxaliplatin (4mg/kg) was administered intraperitoneally twice a week for 4weeks. Cold hyperalgesia was assessed using the acetone test and mechanical allodynia was evaluated using the von Frey test. Key findings Repeated injection of oxaliplatin induced cold hyperalgesia on day 5 and mechanical allodynia on day 28. A single administration of neurotropin transiently relieved both pain behaviors. The analgesic effect of neurotropin was inhibited by pretreatment with 5-HT1A, 5-HT2, 5-HT3, and α2 receptor antagonists and by monoamine depletion. Moreover, the analgesic effect of neurotropin was abolished by intrathecal injection of pertussis toxin, a Gi protein inhibitor. Significance These results suggest that neurotropin is effective in relieving oxaliplatin-induced neuropathy, and that Gi protein-coupled receptors in the monoaminergic descending pain inhibitory system may be involved in the analgesic effect of neurotropin. Neurotropin may have clinical potential for the treatment of oxaliplatin-induced neuropathies.

There are no comments yet on this publication. Be the first to share your thoughts.